Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with
a poor prognosis and no known cure. Survival time is often short because of limited …

Abstract Background The American Cancer Society, Centers for Disease Control and
Prevention, National Cancer Institute, and North American Association of Central Cancer …

Importance Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …

PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …

Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

PURPOSE The role of maintenance therapy for gastric (GC) or gastroesophageal junction
cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

Background In this phase I/II trial, we evaluated the safety and effectiveness of
pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from …